H.R. 9040, Drug Price Control Legislation. Quorum's AI analysis reads it as a net benefit — and names who gains.
H.R. 9040 · Net good
What it does
This bill creates a federal Prescription Drug Price Regulatory Commission that will recommend 'fair prices' for all approved prescription drugs, which the Secretary of HHS will then publish and enforce. Manufacturers must sell drugs at or below these government-set prices to patients, pharmacies, hospitals, and providers, or face civil penalties of up to 10 times the overcharge amount. The bill also grants the government march-in rights to patent licenses and Defense Production Act authority if supply is inadequate.
The analysis names patients and consumers (lower out-of-pocket drug costs) — and 2 more groups — among the beneficiaries.
The trade-off
The bill grants the President Defense Production Act authority to compel domestic drug manufacturing if foreign supply is deemed unreliable—a significant expansion of executive power over pharmaceutical production that could affect supply chains globally.
The analysis put a high warning level on this bill. Transparency scores 65%, and the analysis found no provisions unrelated to the bill's subject.
Who is behind it
Filed by Brad Sherman.